IMPACT OF FAMILY HISTORY ON RISK OF PROGRESSION OF MGUS TO MULTIPLE MYELOMA: A POPULATION-BASED STUDY
(Abstract release date: 05/19/16)
EHA Library. Aradóttir K. 06/09/16; 132813; E1264
Disclosure(s): Nothing to disclose.
Ms. Kristrún Aradóttir
Contributions
Contributions
Abstract
Abstract: E1264
Type: Eposter Presentation
Background
Multiple myeloma (MM) is characterized by a neoplastic proliferation of plasma cells in the bone marrow and overproduction of monoclonal immunoglobulins in serum or urine. MM is always preceded by a premalignant condition called monoclonal gammopathy of undetermined significance (MGUS). Individuals with MGUS have a 1-1.5% annual risk of developing MM or a related disease. Furthermore, familial aggregation of MM and MGUS has been described, and first-degree relatives of MGUS and MM patients have a 2-3 fold increased risk of a lymphoproliferative disorder (LP). We have previously shown that survival among MM patients with a family history of a LP have a significantly superior survival compared to sporadic MM. However, the effect of family history of LP on risk of progression among MGUS is unknown.
Aims
The aim of our study was to compare the risk of progression of MGUS to MM or other LPs in MGUS individuals with a family history of LPs compared to sporadic MGUS.
Methods
Individuals with MGUS and their first-degree relatives were identified using nationwide Swedish Registries. Information on malignancies in relatives of MGUS patients was obtained by record-linkages to the Swedish Cancer Registry. A positive family history of LP was defined as MGUS patients having at least one first-degree relative diagnosed with MM, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, Waldenström’s macroglobulinemia, or Hodgkin’s lymphoma. Cox proportional hazard model was used to obtain hazard ratios (HR) and 95% confidence intervals (95% CIs). In statistical analysis all data were adjusted for age, sex, and year at diagnosis.
Results
A total of 24,126 individuals diagnosed with MGUS in 1958-2013 were included in the study of whom 12,504 were male. Median age at diagnosis was 69.7 and 64.6 years in the sporadic and familial groups, respectively. In a total of 1666 MGUS individuals, the disorder progressed to MM. When compared to patients with sporadic MGUS, patients with MGUS and family history of any LP had similar risk of progression to MM (HR 1.17, 95% CI 0.90-1.53, p=0.23). The same was true when compared only to individuals with family history of MM (HR 0.79, 95% CI 0.52-1.20, p=0.26). Subgroup analyses, stratified by gender and different age groups gave similar results (data not shown).
Conclusion
In this large population-based study we have shown that family history of LPs is not a risk factor for progression among MGUS individuals. Our findings are of importance for counseling MGUS individuals with family history and provide information regarding the biology of hereditary LPs.
Session topic: E-poster
Keyword(s): Familial, MGUS, Multiple myeloma, Progression
Type: Eposter Presentation
Background
Multiple myeloma (MM) is characterized by a neoplastic proliferation of plasma cells in the bone marrow and overproduction of monoclonal immunoglobulins in serum or urine. MM is always preceded by a premalignant condition called monoclonal gammopathy of undetermined significance (MGUS). Individuals with MGUS have a 1-1.5% annual risk of developing MM or a related disease. Furthermore, familial aggregation of MM and MGUS has been described, and first-degree relatives of MGUS and MM patients have a 2-3 fold increased risk of a lymphoproliferative disorder (LP). We have previously shown that survival among MM patients with a family history of a LP have a significantly superior survival compared to sporadic MM. However, the effect of family history of LP on risk of progression among MGUS is unknown.
Aims
The aim of our study was to compare the risk of progression of MGUS to MM or other LPs in MGUS individuals with a family history of LPs compared to sporadic MGUS.
Methods
Individuals with MGUS and their first-degree relatives were identified using nationwide Swedish Registries. Information on malignancies in relatives of MGUS patients was obtained by record-linkages to the Swedish Cancer Registry. A positive family history of LP was defined as MGUS patients having at least one first-degree relative diagnosed with MM, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, Waldenström’s macroglobulinemia, or Hodgkin’s lymphoma. Cox proportional hazard model was used to obtain hazard ratios (HR) and 95% confidence intervals (95% CIs). In statistical analysis all data were adjusted for age, sex, and year at diagnosis.
Results
A total of 24,126 individuals diagnosed with MGUS in 1958-2013 were included in the study of whom 12,504 were male. Median age at diagnosis was 69.7 and 64.6 years in the sporadic and familial groups, respectively. In a total of 1666 MGUS individuals, the disorder progressed to MM. When compared to patients with sporadic MGUS, patients with MGUS and family history of any LP had similar risk of progression to MM (HR 1.17, 95% CI 0.90-1.53, p=0.23). The same was true when compared only to individuals with family history of MM (HR 0.79, 95% CI 0.52-1.20, p=0.26). Subgroup analyses, stratified by gender and different age groups gave similar results (data not shown).
Conclusion
In this large population-based study we have shown that family history of LPs is not a risk factor for progression among MGUS individuals. Our findings are of importance for counseling MGUS individuals with family history and provide information regarding the biology of hereditary LPs.
Session topic: E-poster
Keyword(s): Familial, MGUS, Multiple myeloma, Progression
Abstract: E1264
Type: Eposter Presentation
Background
Multiple myeloma (MM) is characterized by a neoplastic proliferation of plasma cells in the bone marrow and overproduction of monoclonal immunoglobulins in serum or urine. MM is always preceded by a premalignant condition called monoclonal gammopathy of undetermined significance (MGUS). Individuals with MGUS have a 1-1.5% annual risk of developing MM or a related disease. Furthermore, familial aggregation of MM and MGUS has been described, and first-degree relatives of MGUS and MM patients have a 2-3 fold increased risk of a lymphoproliferative disorder (LP). We have previously shown that survival among MM patients with a family history of a LP have a significantly superior survival compared to sporadic MM. However, the effect of family history of LP on risk of progression among MGUS is unknown.
Aims
The aim of our study was to compare the risk of progression of MGUS to MM or other LPs in MGUS individuals with a family history of LPs compared to sporadic MGUS.
Methods
Individuals with MGUS and their first-degree relatives were identified using nationwide Swedish Registries. Information on malignancies in relatives of MGUS patients was obtained by record-linkages to the Swedish Cancer Registry. A positive family history of LP was defined as MGUS patients having at least one first-degree relative diagnosed with MM, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, Waldenström’s macroglobulinemia, or Hodgkin’s lymphoma. Cox proportional hazard model was used to obtain hazard ratios (HR) and 95% confidence intervals (95% CIs). In statistical analysis all data were adjusted for age, sex, and year at diagnosis.
Results
A total of 24,126 individuals diagnosed with MGUS in 1958-2013 were included in the study of whom 12,504 were male. Median age at diagnosis was 69.7 and 64.6 years in the sporadic and familial groups, respectively. In a total of 1666 MGUS individuals, the disorder progressed to MM. When compared to patients with sporadic MGUS, patients with MGUS and family history of any LP had similar risk of progression to MM (HR 1.17, 95% CI 0.90-1.53, p=0.23). The same was true when compared only to individuals with family history of MM (HR 0.79, 95% CI 0.52-1.20, p=0.26). Subgroup analyses, stratified by gender and different age groups gave similar results (data not shown).
Conclusion
In this large population-based study we have shown that family history of LPs is not a risk factor for progression among MGUS individuals. Our findings are of importance for counseling MGUS individuals with family history and provide information regarding the biology of hereditary LPs.
Session topic: E-poster
Keyword(s): Familial, MGUS, Multiple myeloma, Progression
Type: Eposter Presentation
Background
Multiple myeloma (MM) is characterized by a neoplastic proliferation of plasma cells in the bone marrow and overproduction of monoclonal immunoglobulins in serum or urine. MM is always preceded by a premalignant condition called monoclonal gammopathy of undetermined significance (MGUS). Individuals with MGUS have a 1-1.5% annual risk of developing MM or a related disease. Furthermore, familial aggregation of MM and MGUS has been described, and first-degree relatives of MGUS and MM patients have a 2-3 fold increased risk of a lymphoproliferative disorder (LP). We have previously shown that survival among MM patients with a family history of a LP have a significantly superior survival compared to sporadic MM. However, the effect of family history of LP on risk of progression among MGUS is unknown.
Aims
The aim of our study was to compare the risk of progression of MGUS to MM or other LPs in MGUS individuals with a family history of LPs compared to sporadic MGUS.
Methods
Individuals with MGUS and their first-degree relatives were identified using nationwide Swedish Registries. Information on malignancies in relatives of MGUS patients was obtained by record-linkages to the Swedish Cancer Registry. A positive family history of LP was defined as MGUS patients having at least one first-degree relative diagnosed with MM, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, Waldenström’s macroglobulinemia, or Hodgkin’s lymphoma. Cox proportional hazard model was used to obtain hazard ratios (HR) and 95% confidence intervals (95% CIs). In statistical analysis all data were adjusted for age, sex, and year at diagnosis.
Results
A total of 24,126 individuals diagnosed with MGUS in 1958-2013 were included in the study of whom 12,504 were male. Median age at diagnosis was 69.7 and 64.6 years in the sporadic and familial groups, respectively. In a total of 1666 MGUS individuals, the disorder progressed to MM. When compared to patients with sporadic MGUS, patients with MGUS and family history of any LP had similar risk of progression to MM (HR 1.17, 95% CI 0.90-1.53, p=0.23). The same was true when compared only to individuals with family history of MM (HR 0.79, 95% CI 0.52-1.20, p=0.26). Subgroup analyses, stratified by gender and different age groups gave similar results (data not shown).
Conclusion
In this large population-based study we have shown that family history of LPs is not a risk factor for progression among MGUS individuals. Our findings are of importance for counseling MGUS individuals with family history and provide information regarding the biology of hereditary LPs.
Session topic: E-poster
Keyword(s): Familial, MGUS, Multiple myeloma, Progression
{{ help_message }}
{{filter}}